Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities
Launched by HADASSAH MEDICAL ORGANIZATION · Jul 5, 2006
Trial Information
Current as of June 19, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with the following disease category will be eligible:
- • Patients with metastatic lung cancer, metastatic GI cancer, metastatic urogenital cancer, skin and soft tissue cancer.
- • Failure to anti-cancer modalties and evidence of progressive disease despite optimal application of all relevant available anti-cancer modalities.
- • Consenting patients.
- • The patient should sign a consent form stating that he/she will make sure to avoid any contact with chicken or any other species of birds.
- Exclusion Criteria:
- • Not fulfilling any of the above criteria.
- • Moribund patients or patients with life-expectancy \<3 months.
- • Karnofsky performance status \<60%.
- • Pregnant or lactating women.
- • Active local or systemic infections requiring treatment.
- • Co-morbidity or life-threatening clinical condtion other than the basic cancer.
About Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a leading healthcare institution based in Jerusalem, Israel, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, HMO leverages its state-of-the-art facilities and multidisciplinary expertise to conduct innovative research across various therapeutic areas. The organization is dedicated to fostering collaboration between clinical researchers, healthcare professionals, and academic institutions, ensuring the highest standards of ethical practice and scientific rigor. HMO's mission is to translate groundbreaking research into effective treatments, ultimately enhancing health outcomes for diverse populations both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Shimon Slavin, MD
Principal Investigator
Hadassah Medical Organization
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials